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chart. RESULTS: An equal number of male and female
were enrolled. For those patient using herbals the mean
age for the Pre-op clinic and SCPC was 60 and 55 years,
respectively. Of those taking herbal medication, 41%
indicated they started after their cancer diagnosis.
Overall, 64–74% of patients spent $25 or less per month
with an additional 23–28% spending up to $100 and
3–8% spending over $100. Patients reported taking
herbal medications to cure their disease, feel more in
control, help with conventional therapy, and help control
symptoms. Sixty-six percent of the SCPC group and 70%
of the Pre-op group had informed one of their physicians
of herbal use. There were no statistical correlations
between any of the demographic or other parameters
report in the survey. CONCLUSION: As the use of herbal
medications and other alternative treatments increase for
the cancer population it is important for health care pro-
fessionals to understand their use by the patient and
incorporate these treatments into the patient care plan.
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FACT-L is a 44-item multidimensional measure of quality
of life developed for use in evaluating treatment of lung
cancer. Patients self-rate items on 0 to 4 scale corre-
sponding to “not at all” and “very much”. Regulatory
and other approval bodies increasingly demand prefer-
ence-weighted measures of outcome. For economic analy-
sis it is generally held that such weights should be utilities.
The pressing need for users of condition-speciﬁc measures
such as FACT-L is a scoring system that meets the require-
ments of regulatory and other non-clinical users. This
paper describes the successful completion of that task.
OBJECTIVES: The primary purpose of the study was to
develop a set of weights for converting FACT-L into 
a index measure for use in cost-utility analysis.
METHODS: The descriptive complexity of FACT-L had
been reduced in a preliminary study that resulted in the
identiﬁcation of 10 key items covering the 6 dimensions
of the FACT-L. These were used to deﬁne 2 sets of 10
health states, each presented in a 14-page questionnaire
together with EQ-5D. Health states were valued on a
0–100 scale corresponding to worst-best possible health.
A value for dead was also recorded. A random sample of
4000 individuals was drawn from the Electoral Registers
of England Scotland and Wales who were mailed ques-
tionnaires during September 2002. RESULTS: Four
hundred twenty-ﬁve (11%) returned a completed ques-
tionnaire. Conjoint analysis and OLS regression were
used to estimate the marginal utilities for the 6 FACT-L
dimensions. Decrements for each of the 10 key FACT-L
items were also computed. Utilities for FACT-L health
states range from 0.738 to 0.146. CONCLUSIONS:
Despite the response rates, valuations from a representa-
tive sample of the general population were obtained for
critical FACT-L items enabling a utility-weighted index
score to be derived from patient self-assessments for use
in economic evaluation.
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OBJECTIVE: To compare the psychosocial status and
functional limitations in prostate cancer patients with
patients diagnosed with other types of cancer in a
national sample of US adults. METHODS: This study
compared perceived health status, mental health status,
and physical limitations among prostate cancer patients
with patients of other cancers using the 1998 Medical
Expenditure Panel Survey (MEPS). Men over 18 years
reported to have only one type of cancer (ICD-9-CM =
140 to 239) were included in the analysis. Men with 
colorectal cancer or lung cancer and women with breast
cancer were selected for further comparison in the health
and mental health status categories. All analyses used
patient-speciﬁc sampling weights provided by MEPS and
were adjusted for age and number of co-morbid condi-
tions. RESULTS: Approximately 750,000 men were iden-
tiﬁed with prostate cancer and an additional 4.6 million
male patients were identiﬁed with one other type of
cancer. Fewer prostate cancer patients reported having
“excellent” or “very good” health (51%) compared to
patients with other oncology diagnoses (66%). Individu-
als with prostate cancer reported poorer health status
than patients with all other types of cancer (2.9 vs. 2.6,
respectively) and poorer mental health (2.3 vs. 2.1,
respectively). Speciﬁcally, compared to men with colorec-
tal cancer, patients with prostate cancer reported poorer
health and mental health status. Prostate cancer patients
also have an increased odds of requiring assistance with
ADL and IADL (1.22 and 1.26, respectively) than
patients with all other types of cancer. CONCLUSIONS:
Despite a prolonged life expectancy, we found that
prostate cancer has a greater impact on patients’ percep-
tion of health than other types of cancer. Prostate cancer
patients also reported more limitations in functional
ability compared to other types of cancer combined.
These ﬁndings indicate that in addition to identifying
treatments that improve important clinical parameters, an
emphasis should be placed on improving other health
attributes important to prostate cancer patients (e.g.,
quality of life, satisfaction with treatment).
